✦ LIBER ✦

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

✍ Scribed by Johannes FE Mann; Roland E Schmieder; Matthew McQueen; Leanne Dyal; Helmut Schumacher; Janice Pogue; Xingyu Wang; Aldo Maggioni; Andrzej Budaj; Suphachai Chaithiraphan; Kenneth Dickstein; Matyas Keltai; Kaj Metsärinne; Ali Oto; Alexander Parkhomenko; Leopoldo S Piegas; Tage L Svendsen; Koon K Teo; Salim Yusuf

Book ID: 117303452
Publisher: The Lancet
Year: 2008
Tongue: English
Weight: 181 KB
Volume: 372
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(08)61236-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Erectile Dysfunction Predicts Cardiovasc

Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials

✍ Shindel, A. 📂 Article 📅 2011 🏛 Elsevier Science ⚖ 46 KB

Trial finds low dose ramipril does not r

Trial finds low dose ramipril does not reduce cardiovascular or renal events in people with type 2 diabetes and albuminuria: Abstracted from: Marre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004; 328(7438): 495–500.

📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 125 KB